Porton Biologics Raises $61 Million for Cell/Gene Therapy CDMO Services

Suzhou Porton Biologics, a gene and cell therapy CDMO service company, closed a $61 million Series A funding. In late 2020, the Phase I part of Porton's GMP facility was approved, and it began offering services that range from process development to clinical production of plasmids, viral vectors and cell therapies. Proceeds from the financing will support Phase II construction. Porton Biologics is a subsidiary of Chongqing-headquartered CDMO Porton Pharma Solutions. More details.... Stock Symbol: (SHA: 300363) Share this with colleagues: // //